Pulmonx Secures $66M in Financing to Support Commercial Acceleration of the Zephyr Valve System, a Minimally-Invasive Treatment for Severe Emphysema

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COPD--Pulmonx announces a $66 million financing round to support the continued global commercial expansion of the Zephyr Valve System for COPD / emphysema.

Click to view original post